Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Liposomal Annamycin |
Synonyms | |
Therapy Description |
Liposomal annamycin (NSC-700363) is a lipophilic form of the doxorubicin with improved drug targeting and reduced toxicity (PMID: 23763920). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Liposomal Annamycin | Annamycin Liposomal|NSC700363|NSC-700363 | Liposomal annamycin (NSC-700363) is a lipophilic form of the doxorubicin with improved drug targeting and reduced toxicity (PMID: 23763920). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03315039 | Phase Ib/II | Liposomal Annamycin | Study of Liposomal Annamycin for the Treatment of Subjects With Acute Myeloid Leukemia (AML) | Completed | USA | 0 |